论文部分内容阅读
目的:探讨不同他汀类调脂药物对冠心病患者血清脂联素的影响。方法:选取明确诊断为冠心病伴高TC血症患者87例,随机分为2组,A组口服阿托伐他汀20mg/d,B组口服普伐他汀20mg/d,其他治疗相同。检测治疗前后血脂和血清脂联素水平。结果:2组治疗后血脂水平明显下降,血清脂联素水平和HDL-C显著高于治疗前,A组优于B组,且起效时间短。结论:2种他汀类调脂药物都可以明显升高冠心病患者的血清脂联素水平,阿托伐他汀在调脂治疗达标时间和治疗达标后血清脂联素升高的程度上优于普伐他汀。
Objective: To investigate the effect of different statins lipid-lowering drugs on serum adiponectin in patients with coronary heart disease. Methods: A total of 87 patients with coronary heart disease and hypercholesteremia were randomly divided into 2 groups. Group A received atorvastatin 20 mg / d, group B received pravastatin 20 mg / d, and other treatments were the same. Blood lipid and serum adiponectin levels were measured before and after treatment. Results: After treatment, serum lipid levels decreased significantly in both groups. Serum levels of adiponectin and HDL-C were significantly higher than those before treatment, and group A was better than group B, and the onset time was short. Conclusions: Both statins and lipid-lowering drugs can significantly increase serum adiponectin levels in patients with coronary heart disease. Atorvastatin is superior to the control group in the degree of lipid-lowering therapy and the level of serum adiponectin after treatment Statin.